<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04525313</url>
  </required_header>
  <id_info>
    <org_study_id>BECOME1</org_study_id>
    <nct_id>NCT04525313</nct_id>
  </id_info>
  <brief_title>The Prediction Model of Avastin Plus Chemotherapy in Unresectable Ras Mutant CRLM Patients</brief_title>
  <official_title>The Prediction Model of Avastin Plus Chemotherapy as First Line Treatment in Unresectable Ras Mutant Colorectal Liver Metastase (CRLM) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      establishment and validation of the prediction model of avastin plus chemotherapy as first&#xD;
      line treatment in simultaneous ras mutant unresectable CRLM patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ras mutant unresectable CRLM patients with primary tumor resection followed by avastin in&#xD;
      combination with chemotherapy were included in this study. The tumor response was assessed by&#xD;
      local MDT group. Based on tumor response, 58 CRLM patients were classified into two groups&#xD;
      (CR+PR vs SD+PD). Primary samples of the two group patients will be sequenced by mass&#xD;
      spectrum. After MS sequencing, a prediction model will be estimated. Another 58 CRLM patients&#xD;
      will be inclued for validation of the prediction model.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>response rate</measure>
    <time_frame>6 months</time_frame>
    <description>response rate will be assessed by local MDT every two months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>overall survival will be assessed by researchers every two months during treatment, and telephone follow-up every three month after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>3 years</time_frame>
    <description>progression free survival will be assessed by local MDT every two months during treatment, and telephone follow-up every three month after treatment</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Liver Metastases</condition>
  <arm_group>
    <arm_group_label>training set</arm_group_label>
    <description>58 unresectable simutaneous CRLM patients with ras mutation accepted Avastin plus chemotherapy treatment after primary tumor resection between 2013.01 and 2017.12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>validation set</arm_group_label>
    <description>another 58 unresectable simutaneous CRLM patients with ras mutation accepted Avastin plus chemotherapy treatment after primary tumor resection between 2018.01 and 2022.12.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      primary tumor proteins of CRLM patients before avastin plus chemotherapy treatment will be&#xD;
      sequenced by mass spectrum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Simultaneous unresectable CRLM patients(ras mutation) with primary tumor resection before&#xD;
        Avastin plus chemotherapy as first line treatment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        age 18-75 years, histologically proven colorectal adenocarcinoma, with liver-dominant&#xD;
        disease, a life expectancy of &gt; 3 months, ras mutation, unresectable simultaneous liver&#xD;
        metastasis, ECOG 0-1, written informed consent for participation in the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        patients with known hypersensitivity reactions to any of the components of the study&#xD;
        treatments, pregnancy or breast-feeding, accepted chemotherapy, radiotherapy and target&#xD;
        therapy before primary tumor resection, other previous malignancy within 5 years, known&#xD;
        drug abuse/alcohol abuse, ECOG&gt;1, legal incapacity or limited legal capacity.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianmin Xu</last_name>
    <phone>+8613501984869</phone>
    <phone_ext>+8613501984869</phone_ext>
    <email>xujmin@aiiyun.com</email>
  </overall_contact>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 21, 2020</study_first_submitted>
  <study_first_submitted_qc>August 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2020</study_first_posted>
  <last_update_submitted>August 23, 2020</last_update_submitted>
  <last_update_submitted_qc>August 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

